Document is current
Any future updates will be listed below
-
Authors
Kantarjian, Hagop https://orcid.org/0000-0002-1908-3307
Borthakur, Gautam https://orcid.org/0000-0001-7679-6453
Daver, Naval https://orcid.org/0000-0001-7103-373X
DiNardo, Courtney D. https://orcid.org/0000-0001-9003-0390
Issa, Ghayas https://orcid.org/0000-0002-4339-8683
Jabbour, Elias https://orcid.org/0000-0003-4465-6119
Kadia, Tapan https://orcid.org/0000-0002-9892-9832
Sasaki, Koji https://orcid.org/0000-0002-9140-0610
Short, Nicholas J. https://orcid.org/0000-0002-2983-2738
Yilmaz, Musa https://orcid.org/0000-0002-4498-4895
Ravandi, Farhad https://orcid.org/0000-0002-7621-377X
- License Information
-
More Information
Article History
Received: 5 July 2024
Revised: 31 August 2024
Accepted: 5 September 2024
First Online: 19 September 2024
Competing interests
: HK reports research grants and honoraria from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Novartis; honoraria from Ipsen Biopharmaceuticals, KAHR Medical, Shenzhen Target Rx, Stemline, Takeda. TK reports grant or research support from BMS, Celgene, Pfizer, Amgen, Jazz, AstraZeneca and Genentech; consultant fees from Agios, Jazz, Genentech and Novartis. CDiN reports research support to institution from Abbvie, Agios, Bayer, Calithera, Cleave, BMS/Celgene, Daiichi-Sankyo and ImmuneOnc; consultant/advisory boards with Abbvie, Agios, Celgene/BMS, Daiichi-Sankyo, ImmuneOnc, Novartis, Takeda and Notable Labs. ND reports research funding from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi-Sankyo, Abbvie, Hanmi, Trovagene, FATE, Amgen, Novimmune, Glycomimetics, and ImmunoGen and has served in a consulting or advisory role for Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Novartis, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen and Agios. GB reports research funding from Bristol‐Myers Squibb, GlaxoSmithKline, Janssen Scientific Affairs, Eli Lilly and Company, Cyclacel, AstraZeneca, AbbVie, Oncoceutics, Arvinas, Cantargia, PTC Therapeutics, Argenx, BioTheryX, and Bioline and personal fees from PTC Therapeutics, Argenx, BioTheryX, and Bioline. GI reports research funding from Celgene, Merck, Kura Oncology, Syndax, Astex and Novartis, and received consultancy or advisory board fees from NuProbe, AbbVie, Novartis, Sanofi, AstraZeneca, Syndax and Kura Oncology. EJ reports research grants and advisory rolls with AbbVie, Adaptive Biotechnologies, Amgen, BMS, Pfizer and Takeda, and advisory role with Genetech. FR reports research funding from BMS, Amgen, Xencor, Macrogenics, Orsenix, Abbvie, Prelude, Astex; consultancy and honoraria from Celgene, BMS, Amgen, Astellas, Xencor, Agios, AstraZeneca and Orsenix.
